নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

astrazeneca limited - candesartan cilexetil 4mg;  ;   - tablet - 4 mg - active: candesartan cilexetil 4mg     excipient: carmellose calcium hyprolose lactose monohydrate macrogol 8000 magnesium stearate maize starch purified water - treatment of hypertension

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

astrazeneca limited - candesartan cilexetil 8mg;  ;   - tablet - 8 mg - active: candesartan cilexetil 8mg     excipient: carmellose calcium ferrous oxide hyprolose lactose monohydrate macrogol 8000 magnesium stearate maize starch purified water - treatment of hypertension

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

astrazeneca limited - ticagrelor 90mg;  ;  ;   - film coated tablet - 90 mg - active: ticagrelor 90mg       excipient: calcium hydrogen phosphate hyprolose hypromellose iron oxide yellow macrogol 400 magnesium stearate mannitol purified talc purified water   sodium starch glycolate titanium dioxide - brilinta, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) · in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg). · in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

astrazeneca limited - exenatide 250 µg/ml;   - solution for injection - 10µg/40µl - active: exenatide 250 µg/ml   excipient: glacial acetic acid mannitol metacresol sodium acetate trihydrate water for injection - adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea but are not achieving adequate glycaemic control. to improve glycaemic control in patients with type 2 diabetes mellitus in combination with a basal insulin with or without metformin and/or a thiozolidinedione.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

astrazeneca limited - exenatide 250 µg/ml;   - solution for injection - 5µg/20µl - active: exenatide 250 µg/ml   excipient: glacial acetic acid mannitol metacresol sodium acetate trihydrate water for injection - adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea but are not achieving adequate glycaemic control. to improve glycaemic control in patients with type 2 diabetes mellitus in combination with a basal insulin with or without metformin and/or a thiozolidinedione.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

astrazeneca limited - gefitinib 250mg - coated tablet - 250 mg - active: gefitinib 250mg excipient: croscarmellose sodium ethanol hypromellose iron oxide red iron oxide yellow lactose monohydrate macrogol 300 magnesium stearate microcrystalline cellulose povidone purified water sodium laurilsulfate titanium dioxide - treatment of patients with locally advanced or metastatic non small cell lung cancer (nsclc) whose tumours express activating mutations of the egfr tyrosine kinase.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

astrazeneca limited - esomeprazole magnesium trihydrate 22.3mg equivalent to 20 mg esomeprazole; naproxen 500mg;   - modified release tablet - 500mg/20mg - active: esomeprazole magnesium trihydrate 22.3mg equivalent to 20 mg esomeprazole naproxen 500mg   excipient: carnauba wax colloidal silicon dioxide croscarmellose sodium glyceryl monostearate hypromellose   plasacryl (alternative part of enteric coat) ink iron oxide yellow macrogol 8000   magnesium stearate methacrylic acid - ethyl acrylate copolymer opadry clear   opadry white opadry yellow polydextrose polysorbate 80 povidone titanium dioxide triethyl citrate - symptomatic treatment of osteoarthritis in patients who are at risk for developing non-steroidal anti-inflammatory drug (nsaid)associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other nsaids is not considered sufficient.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

astrazeneca limited - zolmitriptan 5mg - nasal spray solution - 5 mg - active: zolmitriptan 5mg excipient: citric acid dibasic sodium phosphate dihydrate purified water

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

astrazeneca limited - zolmitriptan 50 mg/ml - nasal spray solution - 5 mg/dose - active: zolmitriptan 50 mg/ml excipient: citric acid dibasic sodium phosphate dihydrate purified water

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

astrazeneca limited - ticagrelor 60mg;  ;  ;   - film coated tablet - 60 mg - active: ticagrelor 60mg       excipient: calcium hydrogen phosphate hyprolose hypromellose iron oxide black iron oxide red macrogol 400 magnesium stearate mannitol purified water   sodium starch glycolate titanium dioxide - brilinta, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) · in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg). · in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.